ArticlePloS one2025
Advanced deep learning-based brain tumor classification using a novel customized CNN and optimized residual network.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Application of hybrid attention guided dual-path residual learning in magnetic resonance imaging diagnosis].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
- NeuroTrustNet: a cost-effective multimodal ensemble framework for brain tumor classification under cross-dataset variability.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The uncontrollable and rapid growth of brain cells can lead to brain tumors. If left untreated, this condition may result in severe health consequences, including death. Accurate detection and classification are the essential steps toward understanding their mechanisms and ensuring effective treatment. Both tasks are challenging, with brain tumor detection being more complex due to variations in tumor size, structure, and location. Many scholars have employed machine learning and deep learning methods for brain tumor detection. Deep learning (DL) methods provide robust solutions for the detection and classification of brain tumors. Large volumes of healthcare imaging data can be analyzed using these techniques to identify and characterize tumors with high accuracy, often surpassing human performance. In this study, we propose two deep learning models, a novel customized Convolutional Neural Network (CNN) and an optimized ResNet101, to classify brain tumor images into four categories: gliomas, pituitary tumors, meningiomas, and no tumor. We used an MRI image dataset from Kaggle, consisting of 3,264 images. We performed five-fold cross-validation on the training and validation set, and a separate test set was used for final evaluation. The average training accuracy across the five-fold was 99.03±0.01% for the novel customized CNN and 99.87±0.03% for optimized ResNet101, and the average validation accuracy was 96.31±0.01% and 97.23±0.03%, respectively. After the cross-validation, the best-performing fold was then selected and evaluated on the test set, achieving training accuracies of 99.05%, 99.91% and testing accuracies of 97.72%, 98.73%, respectively. The optimized ResNet model achieved the highest performance among the two proposed models. Overall, these findings demonstrate the potential of deep learning models in supporting clinical decision-making for brain tumor classification, which may improve survival rates and human health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.